Key Highlights
- Research and development expense rose about 377% to USD 3,892,387.
- Net loss was USD 7,224,070, or USD 7.42 per share.
- Product Revenue was USD 13,942 in the quarter.
- Cash fell to USD 300,623 from USD 3,789,342 at year-end.
The spending is aimed at research, and the cash balance shows the strain. Jupiter Neurosciences (NASDAQ:JUNS) ended September with USD 300,623, down from USD 3,789,342 at year-end, after a third-quarter net loss of USD 7,224,070 versus USD 2,288,034. The loss was USD 7.42 per share versus USD 5.04, compared with an estimated loss of USD 3.75 per share.
Research and development expense was USD 3,892,387 versus USD 816,697, a rise of about 377%. General and administrative expense was USD 1,912,927 versus USD 1,480,356, and total operating expenses were USD 5,805,314 versus USD 2,297,053. The operating loss was USD 5,795,706. Product revenue was USD 13,942, against an estimate of USD 602 thousand, with Cost of Goods Sold of USD 4,334 and Gross Profit of USD 9,608. Interest income was USD 7,223 versus USD 10,212.
Other expenses totaled USD 1,428,364, including a USD 1,252,798 loss on the change in Fair Value of convertible notes and a USD 114,691 loss on the change in fair value of license consideration payable. Interest expense was USD 68,098.
Nine Months
The nine-month net loss was USD 11,560,425 versus USD 6,069,866, or USD 17.28 per share versus USD 13.61. Product revenue was USD 56,839 with gross profit of USD 44,962, and there was no revenue in the prior-year period. Research and Development reached USD 4,903,789, up about 140% or USD 2,860,899, while general and administrative expense was USD 5,642,824. Accrued compensation was USD 528,616 versus USD 1,397,357, prepaid contracts were USD 766,667 and inventory was USD 130,957.
Liabilities, Equity and Share Issuance
Total Assets were USD 1,623,134. Total liabilities fell to USD 2,785,136 from USD 7,395,882, as convertible notes payable at fair value dropped to USD 225,688 from USD 5,298,068, while a license consideration payable of USD 1,058,546 appeared. The stockholders' Deficit was USD 1,162,002, with additional paid-in Capital of USD 45,065,317 and an accumulated deficit of USD 46,227,451.
In the quarter the company issued 132,867 shares under a license agreement, issued 199,861 shares to settle notes and interest and sold shares under an equity line for USD 87,055. It also completed a registered direct offering of 307,692 shares, with net proceeds of about USD 1.86 million.
Weighted average shares were 973,633 versus 453,865, and 1,318,521 common shares were outstanding versus 459,286 at year-end. The per-share loss therefore reflects both a far larger loss and a larger weighted share count.
The Business
Based in Palm Beach Gardens, Florida, the clinical-stage pharmaceutical company is built around JOTROL, a patented micellar resveratrol formulation in an ongoing Phase IIa study in Parkinson's disease. It is also expanding into a consumer longevity line called Nugevia, which supports mental clarity, skin health and mitochondrial function. Cash use against the USD 300,623 balance, further financing, the Parkinson's study and Nugevia sales are the points to follow.




_11_19_2026_19_57_40_035532.jpg)

Please wait processing your request...